CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
An open label trial of anakinra to prevent respiratory failure in covid-19
Authors
E. Kyriazopoulou Panagopoulos, P. Metallidis, S. Dalekos, G.N. Poulakou, G. Gatselis, N. Karakike, E. Saridaki, M. Loli, G. Stefos, A. Prasianaki, D. Georgiadou, S. Tsachouridou, O. Petrakis, V. Tsiakos, K. Kosmidou, M. Lygoura, V. Dareioti, M. Milionis, H. Papanikolaou, I.C. Akinosoglou, K. Myrodia, D.-M. Gravvani, A. Stamou, A. Gkavogianni, T. Katrini, K. Marantos, T. Trontzas, I.P. Syrigos, K. Chatzis, L. Chatzis, S. Vechlidis, N. Avgoustou, C. Chalvatzis, S. Kyprianou, M. van der Meer, J.W.M. Eugen-Olsen, J. Netea, M.G. Giamarellos-Bourboulis, E.J.
Publication date
1 January 2021
Publisher
Abstract
Background It was studied if early suPAR-guided anakinra treatment can prevent severe respiratory failure (SRF) of COVID-19. Methods 130 patients with suPAR ≥6 ng/ml were assigned to subcutaneous anakinra 100mg once daily for 10 days. Primary outcome was SRF incidence by day 14 defined as any respiratory ratio below 150 mmHg necessitating mechanical or non-invasive ventilation. Main secondary outcomes were 30-day mortality and inflammatory mediators; 28-day WHO-CPS was explored. Propensity-matched standard-of care comparators were studied. Results 22.3% with anakinra treatment and 59.2% comparators (hazard ratio, 0.30; 95%CI, 0.20-0.46) progressed into SRF; 30-day mortality was 11.5% and 22.3% respectively (hazard ratio 0.49; 95% CI 0.25-0.97). Anakinra was associated with decrease in circulating interleukin (IL)-6, sCD163 and sIL2-R; IL-10/IL-6 ratio on day 7 was inversely associated with SOFA score; patients were allocated to less severe WHO-CPS strata. Conclusions Early suPAR-guided anakinra decreased SRF and restored the pro-/anti-inflammatory balance. Trial Registration: ClinicalTrials.gov, NCT04357366. © 2021, eLife Sciences Publications Ltd. All rights reserved
Similar works
Full text
Available Versions
Pergamos : Unified Institutional Repository / Digital Library Platform of the National and Kapodistrian University of Athens
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:lib.uoa.gr:uoadl:2997204
Last time updated on 10/02/2023